Protocol Ledger

NCT06235697 · Phase III · RECRUITING

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Interventional Phase III clinical trial protocol NCT06235697 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-25 Enrollment: 710 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06235697
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)710 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06235697
Protocol FieldVerified Registry Value
NCT IdentifierNCT06235697
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment710 participants (ESTIMATED)
Registered Start Date2024-04-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI